Published in Arch Dermatol on June 01, 1993
Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va. Protein Sci (1997) 1.04
Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C. J Clin Invest (1997) 0.83
Coumarin-induced skin necrosis. Arch Dermatol (1993) 0.82
Severe congenital protein C deficiency: the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications. Biologics (2008) 0.82
Fulminant meningococcal septic shock in a boy with combined inherited properdin and protein C deficiency. Clin Exp Immunol (1995) 0.77
Secretion of human protein C in mouse milk. Int J Mol Sci (2015) 0.76
Inherited thrombophilia: memorandum from a joint WHO/International Society on Thrombosis and Haemostasis meeting. Bull World Health Organ (1997) 0.75
Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database. AJR Am J Roentgenol (1997) 7.62
A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell (1999) 6.82
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med (1999) 4.44
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med (2001) 4.33
The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem (1973) 4.24
Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg-->Gln mutation in the gene for factor V. N Engl J Med (1994) 4.00
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
The separation of active and inactive forms of heparin. Biochem Biophys Res Commun (1976) 2.91
Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med (1990) 2.82
Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature (1992) 2.73
The Munich Polypectomy Study (MUPS): prospective analysis of complications and risk factors in 4000 colonic snare polypectomies. Endoscopy (2005) 2.49
Benefits versus risks from mammography: a critical reassessment. Cancer (1996) 2.43
Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology (1990) 2.36
Anticoagulant action of heparin. Nature (1973) 2.26
Isolation of a src homology 2-containing tyrosine phosphatase. Proc Natl Acad Sci U S A (1992) 2.22
MIPS: analysis and annotation of genome information in 2007. Nucleic Acids Res (2007) 2.21
Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance. Thromb Haemost (2001) 2.16
A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest (1998) 2.08
Actions and interactions of antithrombin and heparin. N Engl J Med (1975) 2.06
Current medicolegal and confidentiality issues in large, multicenter research programs. Am J Epidemiol (2000) 2.06
Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost (2004) 2.04
Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan. J Biol Chem (1986) 2.02
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin. Circ Res (1980) 2.00
Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin. Possible role of a platelet endoglycosidase. J Biol Chem (1982) 1.99
Isolation and characterization of endothelial progenitor cells from mouse embryos. Development (1998) 1.94
[HYGEA (Hygiene in gastroenterology--endoscope reprocessing): Study on quality of reprocessing flexible endoscopes in hospitals and in the practice setting]. Z Gastroenterol (2002) 1.93
Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost (2004) 1.91
Mast cell clones: a model for the analysis of cellular maturation. J Cell Biol (1982) 1.91
PR39, a peptide regulator of angiogenesis. Nat Med (2000) 1.90
Contribution of monosaccharide residues in heparin binding to antithrombin III. Biochemistry (1985) 1.89
Chemistry of the hemostatic mechanism and its relationship to the action of heparin. Fed Proc (1977) 1.83
Correlation between structure and function of heparin. Proc Natl Acad Sci U S A (1979) 1.83
An antiproliferative heparan sulfate species produced by postconfluent smooth muscle cells. J Cell Biol (1985) 1.83
Plasma protein S deficiency in familial thrombotic disease. Blood (1984) 1.82
Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. J Clin Endocrinol Metab (2000) 1.78
Molecular heterogeneity of inherited antithrombin III deficiency. N Engl J Med (1983) 1.75
Natural anticoagulant mechanisms. J Clin Invest (1984) 1.75
Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment. J Cell Biol (1997) 1.74
Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry (1984) 1.70
Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP) Thromb Haemost (1999) 1.69
Relationship between markers of activated coagulation, their correlation with inflammation, and association with coronary heart disease (NPHSII). J Thromb Haemost (2007) 1.67
Structure-function relationships of heparin species. Proc Natl Acad Sci U S A (1978) 1.65
Relationship of plasma leucine and alpha-ketoisocaproate during a L-[1-13C]leucine infusion in man: a method for measuring human intracellular leucine tracer enrichment. Metabolism (1982) 1.65
Binding of disease-associated prion protein to plasminogen. Nature (2000) 1.64
D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost (2006) 1.62
The quality of life in adult female patients with congenital adrenal hyperplasia: a comprehensive study of the impact of genital malformations and chronic disease on female patients life. Eur J Pediatr (1995) 1.61
Clinical response to dietary fiber treatment of chronic constipation. Am J Gastroenterol (1997) 1.61
BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost (2005) 1.60
Expression of heparan sulfate D-glucosaminyl 3-O-sulfotransferase isoforms reveals novel substrate specificities. J Biol Chem (1999) 1.58
Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood (2000) 1.58
Multiple isoforms of heparan sulfate D-glucosaminyl 3-O-sulfotransferase. Isolation, characterization, and expression of human cdnas and identification of distinct genomic loci. J Biol Chem (1999) 1.58
Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci U S A (1995) 1.58
Inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem (1976) 1.56
Heparinlike molecules with anticoagulant activity are synthesized by cultured endothelial cells. Biochem Biophys Res Commun (1985) 1.56
Process quality and incidence of acute complications in a series of more than 230,000 outpatient colonoscopies. Endoscopy (2009) 1.56
Salivary cortisol levels throughout childhood and adolescence: relation with age, pubertal stage, and weight. Pediatr Res (1995) 1.54
Species-dependent variability of ADAMTS13-mediated proteolysis of human recombinant von Willebrand factor. J Thromb Haemost (2009) 1.52
Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol (2000) 1.51
[High dose fibrinogen administration for acute therapy of coagulopathy during massive perioperative transfusion]. Anaesthesist (2005) 1.51
Enzymatic modification of heparan sulfate on a biochip promotes its interaction with antithrombin III. Biochem Biophys Res Commun (2000) 1.51
Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest (1994) 1.50
Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium. J Clin Invest (1984) 1.48
Haemostatic changes that constitute the hypercoagulable state. Lancet (1991) 1.47
The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem (1980) 1.47
Isolation and characterization of heparin from human lung. J Clin Invest (1979) 1.46
Heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3A sulfates N-unsubstituted glucosamine residues. J Biol Chem (1999) 1.45
Multiple functional domains of the heparin molecule. Proc Natl Acad Sci U S A (1981) 1.45
Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol (1988) 1.44
Growth hormone improves height in patients with juvenile idiopathic arthritis: 4-year data of a controlled study. J Pediatr (2003) 1.44
Activated protein C concentrate for the treatment of meningococcal endotoxin shock in rabbits. Shock (1998) 1.43
[Quality assurance in coloscopy in private practice and the hospital. The Gastroenterology Quality Circle (GEQC) Munich]. Dtsch Med Wochenschr (1996) 1.43
Purification and properties of human platelet heparitinase. J Biol Chem (1982) 1.42
Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest (1980) 1.42
Molecular cloning and expression of two distinct cDNA-encoding heparan sulfate proteoglycan core proteins from a rat endothelial cell line. J Biol Chem (1992) 1.41
Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta. J Cell Biol (1990) 1.40
Characterization of two naturally occurring mutations in the second epidermal growth factor-like domain of factor VII. Blood (1999) 1.40
Intermittent microalbuminuria in children with type 1 diabetes mellitus without clinical evidence of nephropathy. Eur J Pediatr (1988) 1.39
[Perioperative management of patients with hemophilia]. Anaesthesist (2014) 1.39
Growth hormone deficiency in children with chromosomal abnormalities. Arch Dis Child (1990) 1.39
CYP21 mutations in simple virilizing congenital adrenal hyperplasia. J Mol Med (Berl) (2001) 1.39
Biologic actions of heparin. Semin Hematol (1977) 1.38
Mechanisms underlying increased platelet reactivity in patients with peripheral arterial disease. Preliminary results. Int Angiol (1999) 1.38
[Fresh plasma and concentrates of clotting factors for therapy of perioperative coagulopathy: what is known?]. Anaesthesist (2006) 1.38
The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A (1994) 1.36
The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood (1995) 1.35
Microvascular heparin-like species with anticoagulant activity. Am J Physiol (1983) 1.34
Inherited thrombophilia: Part 2. Thromb Haemost (1996) 1.34
Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type 1 diabetes. Exp Clin Endocrinol Diabetes (2001) 1.32
Binding of lipoprotein lipase to endothelial cells in culture. J Biol Chem (1981) 1.31
The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood (1987) 1.31